Vomiting

1 paper

Humans1

Trial sponsors

Merck & Co.
Company4 trialsPhase 4773 people
GSK
Company1 trialPhase 31,840 people
Dr. Stephen Freedman
2 trialsPhase 41,543 people
Yonsei University
2 trialsPhase 4217 people
Jun Zhu
1 trialPhase 4130 people
Assiut University
1 trialPhase 4120 people
Federal University of São Paulo
1 trialPhase 440 people
Radboud University Medical Center
1 trialPhase 420 people

Latest

22 in 12 months

Journal of Oral Pathology & Medicine8 Oct

Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical Insights

ReviewGLP-1 receptor agonists

Contemporary Clinical Trials2 Oct

Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties

Trial in peopleSurvodutide

Diabetes, Obesity & Metabolism18 Sep

Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial

Randomised trial in 120 peopleOverweight

Journal of Psychopharmacology16 Sep

Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials

Meta-analysis of randomised trialsGLP-1 receptor agonists

American Journal of Clinical Oncology10 Aug

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Adverse Events in Patients Receiving Platinum Analog-Based Chemotherapy

Cohort study of 200 peopleGLP-1 receptor agonists

Endocrine Practice9 Aug

Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis

Meta-analysisEnd-stage renal disease

Case Reports in Neurology4 Aug

Acute Nutritional Axonal Neuropathy in the Setting of Semaglutide-Associated Gastrointestinal Intolerance: A Case Report

Case reportSemaglutide

ADA Scientific Sessions 2026 Abstract7 Jun

RAY1225, a Biweekly Biased GLP-1/GIP RA for Weight Management: A Phase 2 Trial in Chinese Overweight/Obese Adults (REBUILDING-1)

Trial in peopleInterventions

ADA Scientific Sessions 2026 Abstract7 Jun

Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial

Trial in peopleInterventions

ADA Scientific Sessions 2026 Abstract6 Jun

Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1

Trial in peopleInterventions